Ca2+-dependent, stimulus-specific modulation of the plasma membrane Ca2+ pump in hippocampal neurons.
The plasma membrane Ca(2+) ATPase (PMCA) plays a major role in restoring Ca(2+) to basal levels following transient elevation by neuronal activity. Here we examined the effects of various stimuli that increase [Ca(2+)](i) on PMCA-mediated Ca(2+) clearance from hippocampal neurons. We used indo-1-based microfluorimetry in the presence of cyclopiazonic acid to study the rate of PMCA-mediated recovery of Ca(2+) elevated by a brief train of action potentials. [Ca(2+)](i) recovery was described by an exponential decay and the time constant provided an index of PMCA-mediated Ca(2+) clearance. PMCA function was assessed before and for >or=60 min following a 10-min priming stimulus of either 100 microM N-methyl-d-aspartate (NMDA), 0.1 mM Mg(2+) (reduced extracellular Mg(2+) induces intense excitatory synaptic activity), 30 mM K(+), or control buffer. Recovery kinetics slowed progressively following priming with NMDA or 0.1 mM Mg(2+); in contrast, Ca(2+) clearance initially accelerated and then slowly returned to initial rates following priming with 30 mM K(+)-induced depolarization. Treatment with 10 muM calpeptin, an inhibitor of the Ca(2+) activated protease calpain, prevented the slowing of kinetics observed following treatment with NMDA but had no affect on the recovery kinetics of control cells. Calpeptin also blocked the rapid acceleration of Ca(2+) clearance following depolarization. In calpeptin-treated cells, 0.1 mM Mg(2+) induced a graded acceleration of Ca(2+) clearance. Thus in spite of producing comparable increases in [Ca(2+)](i), activation of NMDA receptors, depolarization-induced activation of voltage-gated Ca(2+) channels and excitatory synaptic activity each uniquely affected Ca(2+) clearance kinetics mediated by the PMCA.
Ferragamo
Michael J
MJ
Department of Biology, Gustavus Adolphus College, Saint Peter, Minneapolis, MN, USA.
Reinardy
Jessica L
JL
Thayer
Stanley A
SA
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004151:Dipeptides / Q000494:pharmacology; D004558:Electric Stimulation / Q000379:methods; D004622:Embryo, Mammalian; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D006624:Hippocampus / Q000166:cytology*; D008274:Magnesium / Q000494:pharmacology; D016202:N-Methylaspartate / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D018408:Patch-Clamp Techniques / Q000379:methods; D053499:Plasma Membrane Calcium-Transporting ATPases / Q000378:metabolism*; D011188:Potassium / Q000494:pharmacology; D051381:Rats
D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D018690:Excitatory Amino Acid Agonists; C071482:calpeptin; D016202:N-Methylaspartate; D053499:Plasma Membrane Calcium-Transporting ATPases; D008274:Magnesium; D011188:Potassium; D002118:Calcium